What is StemoniX?
StemoniX operates at the intersection of tissue engineering, neural interfacing, and artificial intelligence. The company specializes in the development of engineered human brain models that accurately replicate complex neurological functions, including memory, learning, and cognition. Through its flagship CNS-3D and PNS-3D product lines, StemoniX provides critical tools for researchers and developers engaged in drug discovery and the creation of novel neurological therapies. By bridging the gap between traditional laboratory models and human physiological responses, the firm is effectively reducing the risks associated with pharmaceutical development and enhancing the precision of therapeutic testing.
How much funding has StemoniX raised?
StemoniX has raised a total of $23.3M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$6M
Series B
$14.4M
Debt
$350K
Angel/Seed (2016): $2.5M, investors not publicly disclosed
Series A (2017): $6M led by Exponential.io
Series B (2019): $14.4M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Key Investors in StemoniX
Exponential.io
Exponential Group is a software-focused investment entity that provides strategic capital to high-growth technology firms.
Undisclosed Investors
PPP
Public-Private Partnership
What's next for StemoniX?
With the recent capital deployment, StemoniX is poised to scale its operational capacity and expand its footprint in the global drug discovery market. The strategic focus will likely shift toward enhancing the throughput of its neural modeling platforms and deepening its integration with AI-driven analytical tools. As the demand for more accurate, human-centric neurological testing models grows, StemoniX is strategically positioned to become a foundational partner for pharmaceutical enterprises seeking to streamline their pipeline development. Future milestones will likely involve the commercialization of advanced CNS-3D applications and the expansion of its service offerings to meet the rigorous requirements of clinical-stage neurological research.
See full StemoniX company page
